Inhibition of this regulatory mechanism results in the development and progression of atherosclerosis, suggesting that direct targeting of the AMPK-HMGCR signalling cascade may be an attractive therapeutic option for suppressing the development and progression of atherosclerosis and thus reduce cardiovascular risks. This evidence concerns the gene HMGCR and atherosclerosis.